RARE Grant Program – Research Accelerating RUNX1 Exploration
Two-year grant to accelerate druggable pathway discovery and develop interception/prevention therapeutics for RUNX1-FPD—aimed at stopping progression from clonal hematopoiesis to MDS/AML and preventing blood cancer.
Eligibility Criteria:
-
Nonprofit host institutions worldwide; no citizenship restrictions.
-
PI must hold an MD, PhD, or equivalent and have relevant expertise in hematopoiesis and/or immunology.
-
Proposals must align with RUNX1-FPD prevention/interception goals; translational potential prioritized.
-
High-priority topics include clonal hematopoiesis with germline RUNX1, adaptive vs. maladaptive clones, and inflammation resistance mechanisms.
Funding Details:
-
USD 250,000 total over 2 years (≤ USD 125,000/year).
-
Direct costs only; no indirect costs. NIH salary cap applies; no renewals (one no-cost extension possible).
-
Allowable: fringe, travel, supplies, small equipment; subawards permitted (institution disburses).
-
Required resource/data sharing plan and interim/annual/final reports; limited carryover with justification.
Deadline:
-
Proposals due: December 11, 2025 (8:00 PM ET).
-
Notification: February 2026.
-
Project period: April 2026 – April 2028.
Where to Go for Further Information:
-
Apply via ProposalCentral (search Alex’s Lemonade Stand Foundation).
-
Program contacts: [email protected] (RRP) and [email protected] (ALSF).
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023